Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure☆
References (30)
- et al.
Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter
Am J Cardiol
(1989) - et al.
Different cardiodepressant potency of various calcium antagonists in human myocardium
Am J Cardiol
(1990) - et al.
Differential effects of systemic and intracoronary calcium channel blocking agents on global and regional left ventricular function in conscious dogs
Am Heart J
(1981) - et al.
Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease
Am J Cardiol
(1981) - et al.
Hemodynamic effects of intravenous diltiazem with impaired left ventricular function
Am J Cardiol
(1984) - et al.
Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure
Am J Cardiol
(1991) - et al.
Beneficial hemodynamic effects of intravenous and oral diltiazem in severe congestive heart failure
J Am Coll Cardiol
(1984) - et al.
Central and renal hemodynamic effects and hormonal response to diltiazem in severe congestive heart failure
Am J Cardiol
(1987) - et al.
Beneficial effects of long-term diltiazem treatment in dilated cardiomyopathy
J Am Coll Cardiol
(1989) - et al.
A placebocontrolled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study
J Am Coll Cardiol
(1991)
Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter
Am J Cardiol
Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion
Am Heart J
Intravenous diltiazem in patients with atrial fibrillation/atrial flutter: a pilot dose-response study
Drug Invest
Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study
Ann Intern Med
The comparative effects of diltiazem and verapamil on atrioventricular conduction and atrioventricular reentry tachycardia
Circ Res
Cited by (90)
The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation
2020, Canadian Journal of CardiologyMetoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction
2019, American Journal of Emergency MedicineCitation Excerpt :These patients were on therapy for 12 to 52 months, with a mean duration of 25 months [6]. Prior studies, as well as this study; indicate diltiazem is safe in the acute setting [12,16-18]. Both metoprolol and diltiazem act as negative inotropes acutely but beta-blockers provide long term neurohormonal benefits [19].
The authors respond “Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction”
2018, American Journal of Emergency MedicineComparison of Weight-Based Dose vs. Standard Dose Diltiazem in Patients with Atrial Fibrillation Presenting to the Emergency Department
2016, Journal of Emergency MedicineCitation Excerpt :Hypotension was evaluated as a side effect of the dosing regimens. Based on previous studies, we assumed the success rate of a single bolus dose of diltiazem would be 75% (12,14−16,19). A sample size of 292 patients in both groups (a total sample of 584) was calculated to afford 80% power to detect a 10% noninferiority margin for successful treatment between the groups.
Practical management of postoperative atrial fibrillation after noncardiac surgery
2014, Journal of the American College of SurgeonsAtrial Fibrillation
2013, Hospital Medicine Clinics
- ☆
This study was supported by a grant from Marion Merrell Dow Inc., Kansas City, Missouri.